App-Quantinova.ai

Transforming end of life care for patients with lymphoma – understanding training needs within the haematology department of a major acute teaching hospital

L. Pereira - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Simulating haematological emergencies: a pilot course for medical trainees

L. Y. Chen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenic Sepsis

Methadone hydrochloride

Quality of life in survivors of adult haematological malignancy

A. Immanuel - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

The haemato‐oncology patient experience of the process of palliative care in the last year of life: a constructivist grounded theory study

K. Campbell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

The role of a multiple myeloma patient support programme in patient management – interim data, December 2019

M. Fowles - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Ixazomib

Development of a regional palliative care guideline on the use of anticoagulation in palliative and end of life care

K. Moss - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Methadone hydrochloride

Four‐year follow‐up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma

G. Cook - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

Tailoring treatment for patients with newly diagnosed high‐risk myeloma – feasibility results of the UKMRA OPTIMUM (MUKnine) trial

M. Jenner - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Multiple Myeloma

Cyclophosphamide

Phase 3, open‐label, non‐inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba

M. Kaiser - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Hyaluronidase

Pomalidomide, bortezomib and dexamethasone after one prior line of therapy in bortezomib‐pretreated multiple myeloma: a subanalysis of the OPTIMISMM phase 3 trial

J. Lindsay - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Dexamethasone

Ixazomib‐dexamethasone versus physician's choice in patients with relapsed/refractory systemic AL amyloidosis: primary data from the phase 3 TOURMALINE‐AL1 trial

A. D. Wechalekar - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Multiple Myeloma

Cyclophosphamide

ELEVATE‐TN: a phase 3, multicentre, open‐label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment‐naive chronic lymphocytic leukaemia (TN‐CLL)

T. Munir - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

Five years on: a real‐world observational study of patients receiving ibrutinib for relapsed/refractory MCL from the UK and Ireland

D. Tucker - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mantle cell lymphoma

Bendamustine

A 10‐year analysis of outcomes for advanced‐stage Hodgkin lymphoma comparing extended follow‐up of the multinational RATHL trial with real‐world patients treated with ABVD or escalated BEACOPP in the East of England

J. Russell - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Real‐world data of high‐grade lymphoma patients treated with CD19 CAR‐T in the UK

A. Kuhnl - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Axicabtagene ciloleucel

Sequential MATRIX‐RICE therapy followed by autologous stem cell transplant in patients with diffuse large B‐cell lymphoma and secondary central nervous system involvement: the International Extranodal Lymphoma Study Group‐42 Phase II (MARIETTA) Trial

K. Cwynarski - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Methotrexate

UK results from the International Sickle Cell World Assessment Survey (SWAY): patients with sickle cell disease (SCD) experience work impairment and decreased productivity

B. Inusa - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Cold stored platelets reverse thrombocytopathy following cardiac surgery

T. Scorer - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Results for the REAL pilot randomised trial of red cell transfusion in acute myeloid leukaemia: is there sufficient evidence of equipoise to support a definitive study?

S. Morton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute promyelocytic leukemia

Hydroxyzine

The use of e‐learning in blood transfusion training: a review of the current situation

Z. Z. Lim - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts